| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
William Blair analyst Sami Corwin downgrades uniQure (NASDAQ:QURE) from Outperform to Market Perform.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target f...
Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $76 to $53.
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's dise...